In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.

BACKGROUND & AIMS Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction and hyperandrogenism and by insulin resistance and related metabolic alterations. Both metformin and anti-androgens, such as spironolactone, are used to ameliorate the different aspects of this disorder. We investigated whether therapy with metformin plus low-dose spironolactone is more effective than metformin alone in PCOS patients. METHODS AND RESULTS Fifty-six PCOS patients were randomized in two groups: group A (28 patients) was treated with metformin (1700 mg/die) and group B (28 patients) was treated with metformin (1700 mg/die) plus low-dose spironolactone (25 mg/die). Anthropometric, hormonal and metabolic parameters were evaluated at baseline and after six months of treatment. After therapy regular menses were restored in approximately 82% of group A patients (P < 0.001) and in 68% of group B patients (P < 0.001). Circulating testosterone, Δ-4-androstenedione and Hirsutism Score (HS) significantly decreased in both groups. However, dehydro-epiandrosterone sulphate significantly decreased only in group B, and HS underwent a stronger reduction in group B (P < 0.001). At baseline, 39/56 (69.6%) patients met the diagnostic criteria for metabolic syndrome, but only one patient met these criteria after treatment. CONCLUSIONS This study confirms the beneficial effects of metformin in PCOS patients. It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone.

[1]  T. Strowitzki,et al.  Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. , 2006, The Journal of clinical endocrinology and metabolism.

[2]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[3]  S. Dwivedi,et al.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  C. Taner,et al.  Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome , 2009, Archives of Gynecology and Obstetrics.

[5]  R. Norman,et al.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[6]  A. Tosti,et al.  Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[7]  J. Glanville,et al.  The use of metformin for women with PCOS undergoing IVF treatment. , 2006, Human reproduction.

[8]  M. Kim,et al.  Hirsutism: implications, etiology, and management. , 1981, American journal of obstetrics and gynecology.

[9]  Julie Brown,et al.  Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. , 2009, The Cochrane database of systematic reviews.

[10]  R. Mathur,et al.  Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. , 1981, Fertility and sterility.

[11]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[12]  T. Wilkin,et al.  The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double‐blind, placebo‐controlled trial , 2006, BJOG : an international journal of obstetrics and gynaecology.

[13]  D. Kurtz,et al.  Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials , 2008 .

[14]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  F. Orio,et al.  Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. , 2009, Endocrine reviews.

[16]  D. Guzick,et al.  A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. , 2004, Fertility and sterility.

[17]  W. Dodson,et al.  The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. , 2011, Fertility and sterility.

[18]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[19]  S Fiorini,et al.  Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[20]  L. Cross,et al.  Spironolactone for Hirsutism in Polycystic Ovary Syndrome , 2005, The Annals of pharmacotherapy.

[21]  G. Mcinnes,et al.  Lack of effect of spironolactone on hair shaft diameter in hirsute females. , 1989, Postgraduate medical journal.

[22]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[23]  E. Wyse,et al.  Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[24]  Julie Brown,et al.  Clomiphene and anti-oestrogens for ovulation induction in PCOS. , 2009, The Cochrane database of systematic reviews.

[25]  P. Claman.  Men at risk: occupation and male infertility. , 2004, Fertility and sterility.

[26]  A. Galluzzo,et al.  The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. , 2011, Human reproduction.

[27]  Z. Rosenwaks,et al.  Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. , 2004, Human reproduction.

[28]  I. Sahin,et al.  Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study , 2008, Advances in Therapy.

[29]  R. Norman,et al.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. , 2010, Human reproduction.

[30]  R. Azziz,et al.  Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. , 1999, Fertility and sterility.